explore -WSS

explore

author：focus 2025-09-29 21:27:36 - browse：9

An import ban of certain Apple Watches officially goes into effect on Tuesday. Justin Sullivan/Getty Images

An import ban of certain Apple Watches officially goes into effect on Tuesday, after the U.S. International Trade Commission deemed the blood oxygen measurement feature too similar to products patented by pulse oximetry company Masimo. It’s the first time Apple has ever faced such a ban.

President Biden had the chance to veto the ban until Christmas day, but he didn’t, as a statement from his trade representative made clear Tuesday morning. Now, Apple has to decide how much it values this feature, and if it’s willing to take a hit on its journey to establish the Apple Watch as a necessary public health tool.

“We strongly disagree with the USITC decision and resulting exclusion order, and are taking all measures to return Apple Watch Series 9 and Apple Watch Ultra 2 to customers in the U.S. as soon as possible,” Apple spokesperson Nikki Rothberg wrote in an email to STAT.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： With heat waves through August, officials warn of health risks

WSS

How a scoliosis diagnosis changed the life of one young dancer

NFL doctors' conflicts of interest could endanger players, report says

Severe weather updates: 1 million customers without power in 11 states as storms pummel East Coast

The biotech scorecard for Q1: 17 stock

Russia promises retaliation after Ukrainian drones hit a Russian tanker in 2nd sea attack in a day

Doctors push to include dialysis machines in emergency stockpile

entertainment

explore

knowledge

Activists slam private health insurers over coverage restrictions

Videos point to link between seizures and unexplained toddler deaths

DIEP, the 'gold standard' of breast reconstruction, is under threat

Election results set back Medicaid expansion plans

The cancer drug shortage isn’t new — and neither are the solutions

Insitro, AI biotech unicorn, brings cash, new research to JPM 2024

Apple is now the first public company to be valued at $3 trillion

J&J to buy cancer drug developer Ambrx Biopharma

Trump demands the U.S. pay no more for drugs than other countries … again

AdventHealth escalates lawsuit against insurance vendor Multiplan

Wikipedia

JPM: CVS says Medicare Advantage patients are impacting profits

Many breast cancer patients receive more radiation than needed

JPM 2024 Day 3: Biotech Updates from Verve, Roivant, etc

Russia promises retaliation after Ukrainian drones hit a Russian tanker in 2nd sea attack in a day

Chronically ill young patients struggle to find fertility info

White House finalizes ITC's import ban of latest Apple Watches

entertainment

explore

hotspot

explore